Clinical Report: Lethal Pneumonitis Induced by Camrelizumab and Erlotinib

Overview

This case study presents a 70-year-old male with metastatic pancreatic carcinoma who developed fatal pneumonitis after treatment with Camrelizumab and Erlotinib. The findings highlight the potential risks associated with combining immunotherapy and targeted therapy in advanced pancreatic cancer.

Background

Incorporate recent statistics or studies to strengthen the background information.

Data Highlights

No numerical data or trial data was provided in the article.

Key Findings

• A 70-year-old male with metastatic pancreatic cancer developed fatal pneumonitis after receiving Camrelizumab and Erlotinib.
• The patient was previously refractory to gemcitabine and nab-paclitaxel.
• Despite steroid and antibiotic treatment, the patient succumbed to respiratory failure.
• This case raises concerns about the safety of combining immunotherapy with Erlotinib in advanced pancreatic cancer.
• Significant caution is advised when administering Erlotinib following immune checkpoint inhibitor therapy.

Clinical Implications

Healthcare professionals should exercise caution when considering the combination of immunotherapy and targeted therapies in patients with advanced pancreatic cancer. Monitoring for respiratory complications is essential, especially in patients receiving Erlotinib after immune checkpoint inhibitors.

Conclusion

This case underscores the potential dangers of combining Camrelizumab and Erlotinib, suggesting that such strategies may not be safe for patients with advanced pancreatic cancer. Further research is needed to establish safe treatment protocols.

Related Resources & Content

1. Frontiers in Oncology, 2026 -- Case Report: Long-term survival with erlotinib for lung cancer with secondary leptomeningeal carcinomatosis
2. The ASCO Post, 2025 -- Camrelizumab Plus Famitinib vs Camrelizumab Alone in Recurrent or Metastatic Cervical Cancer
3. ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer - PubMed
4. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group | Journal of Clinical Oncology
5. the asco post — Camrelizumab Plus Famitinib vs Camrelizumab Alone in Recurrent or Metastatic Cervical Cancer
6. Gastric Cancer — Gallbladder swelling as an indicator of zolbetuximab-related protein-losing enteropathy in a patient with gastric cancer: a case study
7. Differences in the risk of immune-related pneumonitis between PD-1 and PD-L1 inhibitors: a meta-analysis
8. ESMO Clinical Practice Guideline Express Update on the management of metastatic pancreatic cancer - PubMed
9. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group | Journal of Clinical Oncology